B+
Bull case
0%
Probability
Target price
$30.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
PFE
PfizerBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings bull read is that Pfizer delivered a clean Q1 beat/reaffirmation, showed 7% operational growth excluding COVID products, and is getting visible help from newer and acquired brands, which supports the deterministic positive prior if execution continues.
Posture
Constructive
Lead driver
Value
What changed
6 setup hits (3d) with net bullish as of 2026-10-29.
What can break
COVID product erosion remains large, with Comirnaty down 59% operationally and Paxlovid down 63% operationally in Q1 2026.
Momentum
89
Value
63
Sentiment
53
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $27.75 · Bull $30.50 · Bear $22.00Analysis 2026-05-08; returns require an exact persisted reference.
Earnings
29 · Non-qualifying
Next 2026-11-03 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Earnings Setup
As of 2026-10-30 • RankAlpha AI
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $28.99
Why
Momentum89 · Δ7d -10.2
Value63 · Δ7d -0.3
Sentiment53 · Δ7d +2.0
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Earnings surprise screen
29Non-qualifying2026-11-03 bmo
The earnings date and consensus estimates are available, but checked estimate sources show more downward than upward revisions and expected year-over-year declines in EPS and revenue. Product growth and prior beats provide some counterweight, yet no verified positive revenue revision or recent 1.5x-volume signal supports the required pre-event setup.
Screen as of 2026-10-30. Window 2026-10-30 to 2026-11-05.
Confirming evidence
- • 6 setup hits (3d) with net bullish as of 2026-10-29.
- • Next scheduled catalyst: earnings 2026-11-03 · BMO.
- • Pre-earnings setup: 29 / non-qualifying.
Contradictions & invalidation
- • COVID product erosion remains large, with Comirnaty down 59% operationally and Paxlovid down 63% operationally in Q1 2026.
- • Cost of sales increased as a percent of revenue, and R&D expense rose 12% operationally as Pfizer spends more on oncology and obesity programs.
- • The bear read is that earnings quality still relies on offsetting steep COVID declines, cost of sales rose materially, R&D is climbing, and even supportive external coverage framed the bigger recovery as a multi-year process rather than an immediate inflection.
Catalyst clock
2026-11-03 · BMO
Q1 beat and full-year 2026 guidance reaffirmation reset the post-print baseline
Lead driver: Value · See fundamentals
Momentum
89
8% active weight
Current posture
7d trendSoftening
Δ7d
-10.2
Δ21d
+0.2
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-1.0
Sentiment
53
45% active weight
Current posture
7d trendImproving
Δ7d
+2.0
Δ21d
-13.9
Why this grade
Composite grade B. Momentum 89.0 / Value 63.2 / Sentiment 52.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$27.75
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$170.71B
Beta
0.43
Shares Out
5.7B
P/E (TTM)
14.7
P/S (TTM)
2.28
P/FCF (TTM)
213.60
Rev YoY
+2.6%
EPS YoY
-108.6%
Gross Margin
+64.8%
Op Margin
+26.6%
Net Debt
$53.82B
Current Ratio
1.27
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data